LPS-induced up-regulation of CD80, CD83, and CD86 is inhibited by SB203580
| Variable . | Mean % positive (range) . | Mean MCF (range) . | Mean % positive × mean MCF . |
|---|---|---|---|
| CD80 (n = 4) | |||
| O | 31.5 (3.0-64.2) | 1.4 (0.2-3.1) | 42.8 |
| LPS | 74.5 (45.0-88.5) | 2.7 (1.1-4.1) | 203.1 |
| SB | 32.3 (5.0-62.9) | 1.5 (0.2-4.5) | 50.0 |
| SB/LPS | 61.3 (15.0-89.4) | 2.2 (0.7-4.2) | 137.0 |
| CD83 (n = 5) | |||
| O | 39.2 (11.0-82.3) | 0.7 (0.2-1.9) | 29.2 |
| LPS | 81.7 (70.6-96.8) | 1.9 (1.0-5.0) | 156.7 |
| SB | 34.1 (8.0-77.6) | 0.5 (0.1-1.1) | 17.0 |
| SB/LPS | 53.3 (20.0-88.9) | 0.9 (0.4-2.0) | 47.9 |
| CD86 (n = 4) | |||
| O | 8.7 (0.7-20.2) | 1.0 (0.2-2.7) | 8.6 |
| LPS | 67.6 (40.9-77.8) | 2.4 (1.0-4.9) | 161.1 |
| SB | 8.6 (1.3-17.4) | 1.0 (0.1-2.8) | 8.4 |
| SB/LPS | 43.6 (27.3-57.7) | 1.3 (0.4-3.2) | 57.9 |
| DR (n = 4) | |||
| O | 96.7 (94.6-100) | 53.8 (10.8-108) | 5199.8 |
| LPS | 96.0 (94.0-100) | 114.5 (19.7-187.1) | 10 987.7 |
| SB | 96.2 (94.8-100) | 31.1 (7.4-61.1) | 299.4 |
| SB/LPS | 96.2 (94.8-100) | 113.2 (24.5-235) | 10 896.4 |
| CD40 (n = 4) | |||
| O | 90.9 (87.1-93.6) | 8.4 (2.0-18.8) | 767.1 |
| LPS | 90.7 (87.6-94.0) | 20.0 (5.7-47.7) | 1815.8 |
| SB | 92.7 (90.9-94.7) | 6.4 (1.2-12.7) | 590.6 |
| SB/LPS | 93.4 (91.6-95.0) | 15.8 (3.6-34.7) | 1471.9 |
| CD1a (n = 4) | |||
| O | 66.6 (47.1-96.1) | 4.8 (1.2-13.3) | 316.9 |
| LPS | 65.1 (32.7-84.8) | 4.2 (1.0-12.2) | 270.5 |
| SB | 60.1 (42.6-84.5) | 3.4 (0.8-9.7) | 202.1 |
| SB/LPS | 63.7 (43.2-86.9) | 4.2 (1.1-13.1) | 267.4 |
| MP (n = 3) | |||
| O | — | 227.3 (161.8-272) | — |
| LPS | — | 102.0 (43-171) | — |
| SB | — | 195.1 (121.4-292) | — |
| SB/LPS | — | 80.7 (41-128) | — |
| Variable . | Mean % positive (range) . | Mean MCF (range) . | Mean % positive × mean MCF . |
|---|---|---|---|
| CD80 (n = 4) | |||
| O | 31.5 (3.0-64.2) | 1.4 (0.2-3.1) | 42.8 |
| LPS | 74.5 (45.0-88.5) | 2.7 (1.1-4.1) | 203.1 |
| SB | 32.3 (5.0-62.9) | 1.5 (0.2-4.5) | 50.0 |
| SB/LPS | 61.3 (15.0-89.4) | 2.2 (0.7-4.2) | 137.0 |
| CD83 (n = 5) | |||
| O | 39.2 (11.0-82.3) | 0.7 (0.2-1.9) | 29.2 |
| LPS | 81.7 (70.6-96.8) | 1.9 (1.0-5.0) | 156.7 |
| SB | 34.1 (8.0-77.6) | 0.5 (0.1-1.1) | 17.0 |
| SB/LPS | 53.3 (20.0-88.9) | 0.9 (0.4-2.0) | 47.9 |
| CD86 (n = 4) | |||
| O | 8.7 (0.7-20.2) | 1.0 (0.2-2.7) | 8.6 |
| LPS | 67.6 (40.9-77.8) | 2.4 (1.0-4.9) | 161.1 |
| SB | 8.6 (1.3-17.4) | 1.0 (0.1-2.8) | 8.4 |
| SB/LPS | 43.6 (27.3-57.7) | 1.3 (0.4-3.2) | 57.9 |
| DR (n = 4) | |||
| O | 96.7 (94.6-100) | 53.8 (10.8-108) | 5199.8 |
| LPS | 96.0 (94.0-100) | 114.5 (19.7-187.1) | 10 987.7 |
| SB | 96.2 (94.8-100) | 31.1 (7.4-61.1) | 299.4 |
| SB/LPS | 96.2 (94.8-100) | 113.2 (24.5-235) | 10 896.4 |
| CD40 (n = 4) | |||
| O | 90.9 (87.1-93.6) | 8.4 (2.0-18.8) | 767.1 |
| LPS | 90.7 (87.6-94.0) | 20.0 (5.7-47.7) | 1815.8 |
| SB | 92.7 (90.9-94.7) | 6.4 (1.2-12.7) | 590.6 |
| SB/LPS | 93.4 (91.6-95.0) | 15.8 (3.6-34.7) | 1471.9 |
| CD1a (n = 4) | |||
| O | 66.6 (47.1-96.1) | 4.8 (1.2-13.3) | 316.9 |
| LPS | 65.1 (32.7-84.8) | 4.2 (1.0-12.2) | 270.5 |
| SB | 60.1 (42.6-84.5) | 3.4 (0.8-9.7) | 202.1 |
| SB/LPS | 63.7 (43.2-86.9) | 4.2 (1.1-13.1) | 267.4 |
| MP (n = 3) | |||
| O | — | 227.3 (161.8-272) | — |
| LPS | — | 102.0 (43-171) | — |
| SB | — | 195.1 (121.4-292) | — |
| SB/LPS | — | 80.7 (41-128) | — |
Immature MoDCs were split on day 7 of culture and exposed to either diluent control (O), LPS (100 ng/mL), SB203580 (SB; 40 μmol/L), or SB203580 together with LPS for 48 hours, before incubation with fluorochrome-conjugated antibodies directed against cell surface antigens and analysis using a flow cytometer. This table displays the mean percentage of cells that expressed the antigen under consideration together with the mean cell fluorescence (MCF) of the whole population of cells. Each is shown with its range in parentheses. In the final column is the product of these 2 readings. No normalization has been performed. The final row shows the mean MCF of the MoDCs after incubation in FITC-dextran for 60 minutes. It can be seen that the LPS-induced up-regulation of CD80, CD83, and CD86 is inhibited by the p38SAPK inhibitor SB203580, but inhibiting p38SAPK has little or no effect on the LPS-induced changes with regard to CD1a, CD40, HLA-DR, and macropinocytosis.